(Q34275888)

1 August 2017

1 reference

title

Interferon and cytotoxic chemotherapy for the treatment of post-transplant lymphoproliferative disorder (English)

1 reference

post-transplant lymphoproliferative disorder

1 August 2017

main subject

0 references

0 references

1 reference

Davis CL

1

1 reference

1 August 2017

publication date

1 June 2001

1 reference

Transplant Infectious Disease

1 August 2017

published in

1 reference

1 August 2017

volume

3

1 reference

1 August 2017

issue

2

1 reference

1 August 2017

page(s)

108-118

1 reference

Lymphoproliferative disorders after organ transplantation in children

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2001.003002108.X

Treatment of organ transplant-related lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2001.003002108.X

Diagnosis and treatment of transplant-related lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2001.003002108.X

Alpha interferon gene deletions in post-transplant lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2001.003002108.X

Posttransplant lymphoproliferative disorder in pediatric renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2001.003002108.X

The diagnosis and treatment of posttransplant lymphoproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2001.003002108.X

Epstein-Barr virus-associated high-grade anaplastic plasmacytoma in a renal transplant patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2001.003002108.X

Cytokine mRNA profiles in Epstein-Barr virus-associated post-transplant lymphoproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2001.003002108.X

The Epstein-Barr virus LMP1 amino acid sequence that engages tumor necrosis factor receptor associated factors is critical for primary B lymphocyte growth transformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2001.003002108.X

Epstein-Barr virus (EBV)-associated smooth-muscle tumor arising in a post-transplant patient treated successfully for two PT-EBV-associated large-cell lymphomas. Case report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2001.003002108.X

Post-transplant lymphoproliferative disease (PTLD): lymphokine production and PTLD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2001.003002108.X

Epstein-Barr virus and a cellular signaling pathway in lymphomas from immunosuppressed patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2001.003002108.X

Action of Myc in vivo - proliferation and apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2001.003002108.X

Epstein-Barr virus-related disorders in children undergoing renal transplantation with tacrolimus-based immunosuppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2001.003002108.X

Interleukin-18, interferon-gamma, IP-10, and Mig expression in Epstein-Barr virus-induced infectious mononucleosis and posttransplant lymphoproliferative disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2001.003002108.X

Polymorphism of the interleukin-10 gene is associated with susceptibility to Epstein-Barr virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2001.003002108.X

Interferon-alpha affects the immune response in post-transplant lymphoproliferative disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2001.003002108.X

Interleukin-10 in Epstein-Barr virus-associated post-transplant lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2001.003002108.X

Interleukin-6 production in posttransplant lymphoproliferative disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2001.003002108.X

Infection of human endothelial cells with Epstein-Barr virus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2001.003002108.X

Extracorporeal photochemotherapy for Epstein-Barr virus-associated lymphoma after lung transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2001.003002108.X

Elevated pretreatment serum levels of Il-10 are associated with a poor prognosis in Hodgkin's disease, the milan cancer institute experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2001.003002108.X

The management of Epstein-Barr virus associated post-transplant lymphoproliferative disorders in pediatric solid-organ transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2001.003002108.X

Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2001.003002108.X

Interleukin 10 induced c-fos expression in human B cells by activation of divergent protein kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2001.003002108.X

Isolation and expression of human cytokine synthesis inhibitory factor cDNA clones: homology to Epstein-Barr virus open reading frame BCRFI

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2001.003002108.X

Homology of cytokine synthesis inhibitory factor (IL-10) to the Epstein-Barr virus gene BCRFI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2001.003002108.X

Expression of interleukin-10 activity by Epstein-Barr virus protein BCRF1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2001.003002108.X

Interleukin-10 production by a B-cell line derived from human post-transplant lymphoproliferative disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2001.003002108.X

The addition of interferon or high dose cyclophosphamide to standard chemotherapy in the treatment of patients with multiple myeloma: phase III Eastern Cooperative Oncology Group Clinical Trial EST 9486.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2001.003002108.X

Interferon alpha 2b as maintenance therapy in low grade malignant lymphoma improves duration of remission and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2001.003002108.X

Autologous stem cell transplantation in multiple myeloma: results of the European Group for Bone Marrow Transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2001.003002108.X

Autologous peripheral blood stem cell transplantation for multiple myeloma: a report of 259 cases from the Spanish Registry. Spanish Registry for Transplant in MM (Grupo Español de Trasplante Hematopoyético-GETH) and PETHEMA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2001.003002108.X

Multiple myeloma, high-dose treatment and autologous stem cell transplantation--current status

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2001.003002108.X

Epstein-Barr virus infection in renal transplant recipients. Effects of antithymocyte globulin and interferon

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2001.003002108.X

In vitro culture of B-lymphocytes derived from Epstein-Barr-virus-associated posttransplant lymphoproliferative disease: cytokine production and effect of interferon-alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2001.003002108.X

Effects of immunotherapy on experimental immunodeficiency-related lymphoproliferative disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2001.003002108.X

Interferon-alpha signaling promotes nucleus-to-cytoplasmic redistribution of p95Vav, and formation of a multisubunit complex involving Vav, Ku80, and Tyk2

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2001.003002108.X

Interferon-alpha (IFN-alpha) enhances cytotoxicity in healthy volunteers and chronic hepatitis C infection mainly by the perforin pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2001.003002108.X

Effects of maximal exercise on natural killer (NK) cell cytotoxicity and responsiveness to interferon-alpha in the young and old.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2001.003002108.X

Transfer of EBV-specific CTL to prevent EBV lymphoma post bone marrow transplant

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2001.003002108.X

Disruption by interferon-alpha of an autocrine interleukin-6 growth loop in IL-6-dependent U266 myeloma cells by homologous and heterologous down-regulation of the IL-6 receptor alpha- and beta-chains

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2001.003002108.X

Modulation of interleukin-6/interleukin-6 receptor cytokine loop in the treatment of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2001.003002108.X

Sensitivity of an epstein-barr virus-positive tumor line, Daudi, to alpha interferon correlates with expression of a GC-rich viral transcript

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2001.003002108.X

Double-stranded RNA-dependent protein kinase mediates c-Myc suppression induced by type I interferons

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2001.003002108.X

Epstein-Barr virus gene expression in interferon-treated cells. Implications for the regulation of protein synthesis and the antiviral state

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2001.003002108.X

Interferon alpha increases the frequency of interferon gamma-producing human CD4+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2001.003002108.X

Alpha interferon suppresses the cyclin D3 and cdc25A genes, leading to a reversible G0-like arrest

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2001.003002108.X

Differential human multiple myeloma cell line responsiveness to interferon-alpha. Analysis of transcription factor activation and interleukin 6 receptor expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2001.003002108.X

Evidence against a direct cytotoxic effect of alpha interferon and zidovudine in HTLV-I associated adult T cell leukemia/lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2001.003002108.X

Cyclosphosphamide/prednisone for combination immunosuppression and therapy of lymphoproliferative disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2001.003002108.X

Clinical toxicity of the interferons.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2001.003002108.X

High dose interferon treatment in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2001.003002108.X

Recombinant leucocyte interferon A induces steroid-resistant acute vascular rejection episodes in renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2001.003002108.X

Interferon-alpha-induced acute renal allograft rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2001.003002108.X

Controlled clinical trial of prophylactic human-leukocyte interferon in renal transplantation. Effects on cytomegalovirus and herpes simplex virus infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2001.003002108.X

Gene polymorphisms of interleukins 1 and 10 in infectious and autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2001.003002108.X

Axonal neuropathy associated with interferon-α treatment for hepatitis C: HLA-DR immunoreactivity in Schwann cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2001.003002108.X

Posttransplantation lymphoproliferative disorder in liver recipients: characteristics, management, and outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2001.003002108.X

7 January 2021

Post-transplant lymphoproliferative disorder in renal allograft recipients. Clinical experience and risk factor analysis in a single center

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2001.003002108.X

7 January 2021

Interferon-alpha treatment of posttransplant lymphoproliferative disorder in recipients of solid organ transplants

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2001.003002108.X

7 January 2021

Durable remission after aggressive chemotherapy for post-cardiac transplant lymphoproliferation

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2001.003002108.X

7 January 2021

Lymphoproliferative disorders in cardiac transplant recipients are multiclonal lymphomas

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2001.003002108.X

7 January 2021

Induced heteroduplex genotyping of TNF-alpha, IL-1beta, IL-6 and IL-10 polymorphisms associated with transcriptional regulation

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2001.003002108.X

7 January 2021

INTERLEUKIN-10 AND POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDER AFTER KIDNEY TRANSPLANTATION1

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2001.003002108.X

7 January 2021

Cerebrospinal fluid interleukin-10 levels in primary central nervous system lymphoma: a possible marker of response to treatment?

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2001.003002108.X

7 January 2021

OKT3 monoclonal antibodies induce interleukin-6 and interleukin-10: a possible cause of lymphoproliferative disorders associated with transplantation.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2001.003002108.X

7 January 2021

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2001.003002108.X

1 reference

7 January 2021

Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2001.003002108.X

7 January 2021

The treatment of relapsed or refractory intermediate grade non-Hodgkin's lymphoma with autologous bone marrow transplantation followed by cyclosporine and interferon

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2001.003002108.X

7 January 2021

Adjuvant alpha-interferon improves complete remission rates following allogeneic transplantation for multiple myeloma

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2001.003002108.X

7 January 2021

Interleukin-6 sensitizes multiple myeloma cell lines for apoptosis induced by interferon-alpha

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2001.003002108.X

7 January 2021

Genetic differences in the age-associated decrease in inducibility of natural killer cells by interferon-alpha/beta

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2001.003002108.X

7 January 2021

Reversal of human immunodeficiency virus type 1 protein-induced inhibition of natural killer cell activity by alpha interferon and interleukin-2

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2001.003002108.X

7 January 2021

Soluble HLA class I and beta-2-microglobulin plasma concentrations during interferon treatment of chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2001.003002108.X

7 January 2021

In vivo induction of HLA molecules in patients with myeloproliferative syndrome during IFN alpha treatment

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2001.003002108.X

7 January 2021

Anti-proliferative effects of interferons on Daudi Burkitt lymphoma cells: induction of cell differentiation and loss of response to autocrine growth factors

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2001.003002108.X

7 January 2021

Interferon-alpha suppresses the capacity of T cells to help antibody production by human B cells

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2001.003002108.X

7 January 2021

Interferon-alpha and its effects on post-transplant lymphoproliferative disorders

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2001.003002108.X

7 January 2021

Modulation of Apo-1/Fas (CD95)-induced programmed cell death in myeloma cells by interferon-alpha 2

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2001.003002108.X

7 January 2021

Telogen effluvium due to recombinant interferon alpha-2b

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2001.003002108.X

7 January 2021

Peripheral neuropathy during alpha-interferon therapy in a child with Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2001.003002108.X

7 January 2021

Low-dose recombinant leukocyte interferon-alpha treatment of hepatitis C viral infection in renal transplant recipients. A pilot study

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2001.003002108.X

7 January 2021

Preliminary results of treatment of chronic hepatitis C with recombinant interferon alpha in renal transplant patients

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2001.003002108.X

7 January 2021

Adverse effect of low-dose prophylactic human recombinant leukocyte interferon-alpha treatment in renal transplant recipients. Cytomegalovirus infection prophylaxis leading to an increased incidence of irreversible rejections

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2001.003002108.X

7 January 2021

Effects of Interferon-Alpha on Cytomegalovirus Reactivation Syndromes in Renal-Transplant Recipients

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2001.003002108.X

7 January 2021

Acute renal failure in kidney transplant patients treated with interferon alpha 2b for chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2001.003002108.X

7 January 2021

Lymphoproliferative disorders after organ transplantation: a report of 24 cases observed in a single center

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2001.003002108.X

7 January 2021

Management of posttransplant lymphoproliferative disease in pediatric liver transplant recipients receiving primary tacrolimus (FK506) therapy

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2001.003002108.X

7 January 2021

Suppression of the tumorigenic growth of Burkitt's lymphoma cells in immunodeficient mice by cytokine gene transfer using EBV-derived episomal expression vectors

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2001.003002108.X

7 January 2021

10.1034/J.1399-3062.2001.003002108.X

Identifiers

DOI

1 reference

1 August 2017

1 reference